

DAFTAR PUSTAKA

- Adams, D. D., Fastier, F. N., Howie, J. B., Kennedy, T. H., Kilpatrick, J. A., & Stewart, R. D. H. 1974. "Stimulation of the human thyroid by infusions of plasma containing LATS protector". *J Clin Endocrinol Metab*, 39(5), 826-832.
- Bahn RS., 2010. "Graves' ophthalmopathy". *N Engl J Med*; 362:726–738
- Bartalena L, Tanda ML. 2009. "Clinical practice. Graves' ophthalmopathy". *N Engl J Med*;360(10):994–1001.
- Bartalena, L., Baldeschi, L., Boboridis, K., Eckstein, A., Kahaly, G.J., Marcocci, C., Perros, P., Salvi, M. and Wiersinga, W.M., 2016. "The 2016 European thyroid association/European group on Graves' Orbitopathy guidelines for the Management of Graves' Orbitopathy". *Eur thyroid J*, 5(1), hal.9-26.
- Bartley, G. B., Fatourehchi, V., Kadrmas, E. F., JACOBSEN, S. J., Ilstrup, D. M., Garrity, J. A., & Gorman, C. A. 1996. "Clinical features of Graves' ophthalmopathy in an incidence cohort". *Am J Ophthalmol*, 121(3), 284-290.
- Biondi B, Kahaly GJ., 2010. "Cardiovascular involvement in patients with different causes of hyperthyroidism". *NatRev Endocrinol*. 6(8):431–43.
- Brent GA., 2008. "Clinical practice. Graves' disease". *N Engl J Med*, 358(24):2594-605.
- Burch HB, Wartofsky L., 1993. "Graves' ophthalmopathy: current concepts regarding pathogenesis and management". *Endocr Rev*. 14:747–793. 7.
- Cawood TJ, Moriarty P, O'Farrelly C, et al. 2007. "Smoking and thyroid-associated ophthalmopathy: a novel explanation of the biological link". *J Clin Endocrinol Metab*. 2007; 92:59–64
- Chin, Y.H., Ng, C.H., Lee, M.H., Koh, J.W.H., Kiew, J., Yang, S.P., Sundar, G. and Khoo, C.M., 2020. "Prevalence of thyroid eye disease in Graves' disease: A meta- analysis and systematic review". *Clin Endocrinol*, 93(4), hal. 363-374.
- David, T.T., 2000. "A simple maneuver to reposit a subluxed globe". *Arch Ophthalmol*, 118(3), hal.410-411.
- Davies, T. F., 2021. "The pathogenesis of Graves' disease". *Werner and Ingbar's the Thyroid: A Fundamental and Clinical Text. Edited by Braverman LE, Utiger RD. Philadelphia: Lippincott-Raven*, 525-536.
- Diana, T., & Kahaly, G. J., 2018. "Thyroid Stimulating Hormone Receptor Antibodies in Thyroid Eye Disease—Methodology and Clinical Applications". *Ophthalmic Plast Reconstr Surg*, 1. doi:10.1097/iop.0000000000001053.
- Douglas, R. S., McCoy, A. N., & Gupta, S. (Eds.). 2015. "Thyroid Eye Disease". doi:10.1007/978-1-4939-1746-4.
- Dragan LR., Seif SR., Lee DC., 2006. "Longitudinal correlation of thyroid-stimulating immunoglobulin with clinical activity of disease in thyroid-associated orbitopathy". *Ophthalmic Plast Reconstr Surg* 22(1):13–19.

- Eckstein, A. K., Plicht, M., Lax, H., Neuhäuser, M., Mann, K., Lederbogen, S., Morgenthaler, N. G. 2006. "Thyrotropin Receptor Autoantibodies Are Independent Risk Factors for Graves' Ophthalmopathy and Help to Predict Severity and Outcome of the Disease". *J Clin Endocrinol Metab*, 91(9), 3464–3470. doi:10.1210/jc.2005-2813.
- Erb, M.H., Tran, N.H., McCulley, T.J. and Bose, S., 2003. "Exophthalmometry measurements in Asians". *Invest Ophthalmol Vis Sci*, 44(13), hal.662-662.
- European Group on Graves O, Wiersinga WM, Perros P, Kahaly GJ, Mourits MP, Baldeschi L, et al. 2006. "Clinical assessment of patients with Graves' orbitopathy: the European Group on Graves' Orbitopathy recommendations to generalists, specialists and clinical researchers". *Eur J Endocrinol*. 2006;155(3):387-9.
- Fuhrer D., Brix K., Biebertmann H., 2015. "Understanding the Healthy Thyroid State in 2015". *Eur Thyroid J*, 4(Suppl 1):1-8.
- George B., Bartley M., Colum A., Gorman M., 1994. "Diagnostic criteria for Graves' ophthalmopathy". *Am J Ophthalmol*. 1994;119(6):792–5.
- Gerding MN, van der Meer JW, Broenink M, Bakker O, Wiersinga WM, Prummel MF., 2000. "Association of thyrotrophin receptor antibodies with the clinical features of Graves' ophthalmopathy". *Clin Endocrinol (Oxf)*. 2000;52(3):267-71.
- Hart, R.H., Kendall-Taylor, P., Crombie, A. and Perros, P., 2005. "Early response to intravenous glucocorticoids for severe thyroid-associated ophthalmopathy predicts treatment outcome". *Journal of Ocular Pharmacology & Therapeutics*, 21(4), hal.328-336.
- Hesarghatta Shyamasunder, A., & Abraham, P. 2017. "Measuring TSH receptor antibody to influence treatment choices in Graves' disease". *Clin Endocrinol*, 86(5), 652–657. doi:10.1111/cen.13327.
- Horlock, Claire. 2020. "Enzyme-linked immunosorbent assay (ELISA)". Imperial College London, UK. Diakses dari <https://www.immunology.org/public-information/bitesized-immunology/experimental-techniques/enzyme-linked-immunosorbent-assay>
- Huang, Y., Fang, S., Li, D., Zhou, H., Li, B. and Fan, X., 2019. "The involvement of T cell pathogenesis in thyroid-associated ophthalmopathy". *Eye*, 33(2), hal.176-182.
- Jang SY, Shin DY, Lee EJ, Yoon JS. 2014. "Clinical characteristics of Graves' orbitopathy in patients showing discrepancy between levels from TBII assays and TSI bioassay". *Clin Endocrinol* 80:591–597.
- Kauhalinen- Mäkelin, R., Karma, A., Leinonen, E., Löyttyniemi, E., Salonen, O., Sane, T., Setälä, K., Viikari, J., Heufelder, A. and Välimäki, M., 2002. "High dose intravenous methylprednisolone pulse therapy versus oral prednisone for thyroid-associated ophthalmopathy". *Acta OphthalmologicaScandinavica*, 80(3), hal.316-321.
- Kazim, M., Goldberg, R.A. dan Smith, T.J., 2002. "Insights into the pathogenesis of thyroid-associated orbitopathy: evolving rationale for therapy". *Arch of Ophthalmology*, 120(3), hal.380-386.

- Khoo DHC, Ho SC, Seah LL, Fong KS, Tai ES, Chee SP, Eng PH, Aw SE, Fok AC. 1999. "The combination of absent thyroid peroxidase antibodies and high thyroid-stimulating immunoglobulin levels in Graves' disease identifies a group at markedly increased risk of ophthalmopathy". *Thyroid* 9:1175–1180.
- Kubota, S., Ohye, H., Nishihara, E., Kudo, T., Ito, M., Fukata, S., Miyauchi, A. 2005. "Effect of High Dose Methylprednisolone Pulse Therapy Followed by Oral Prednisolone Administration on the Production of Anti-TSH Receptor Antibodies and Clinical Outcome in Graves' Disease". *Endocr J*, 52(6), 735–741. doi:10.1507/endocrj.52.735.
- Li, Z., Cestari, D. M., & Fortin, E., 2018. "Thyroid eye disease. Current Opinion in Ophthalmology, 1". doi:10.1097/icu.0000000000000529.
- Liaboe, C.A., Clark, T.J., Shriver, E.M. and Carter, K.D., 2016. "Thyroid Eye Disease: An Introductory Tutorial and Overview of Disease". *EyeRounds.org*.
- Lytton SD, Ponto KA, Kanitz M, Matheis N, Kohn LD, Kahaly GJ., 2010. "A novel thyroid stimulating immunoglobulin bioassay is a functional indicator of activity and severity of Graves' orbitopathy". *J Clin Endocrinol Metab*. 2010;95(5):2123-31.
- Marcocci, C., Kahaly, G.J., Krassas, G.E., Bartalena, L., Prummel, M., Stahl, M., Altea, M.A., Nardi, M., Pitz, S., Boboridis, K. and Sivelli, P., 2011. "Selenium and the course of mild Graves' orbitopathy". *New England Journal of Medicine*, 364(20), hal.1920-1931.
- McKenzie JM, Zakarija M., 1992. "Fetal and neonatal hyperthyroidism and hypothyroidism due to maternal TSH receptor antibodies". *Thyroid*. 1992; 2:155.
- Mitchell, A. L., Gan, E. H., Morris, M., Johnson, K., Neoh, C., Dickinson, A. J., ... Pearce, S. H. S. 2013. "The effect of B cell depletion therapy on anti-TSH receptor antibodies and clinical outcome in glucocorticoid-refractory Graves' orbitopathy". *Clin Endocrinol*, 79(3), 437–442. doi:10.1111/cen.12141
- Pearce S.H.S., 2008. "Graves' disease". In: Weetman AP, editor. *Autoimmune diseases in endocrinology*, 117–35.
- Prabhakar BS, Bahn RS, Smith TJ., 2003. "Current perspective on the pathogenesis of Graves' disease and ophthalmopathy". *Endocr Rev*. 2003; 24:802–35.
- Rebecca S., 2010. "Mechanisms of Disease Graves' Ophthalmopathy". *The New England Journal of Medicine*. 2010;362:726-38.
- Riskesdas IMD PMK, Eksklusif A. 2013. Kementerian Kesehatan RI. Jakarta; 2013.
- Roos JCP, Paulpandian V, Murthy R. 2019. "Serial TSH-receptor antibody levels to guide the management of thyroid eye disease: the impact of smoking, immunosuppression, radio-iodine, and thyroidectomy". *Eye (Lond)*. 2019;33(2):212-7.
- Sabini, E., Mazzi, B., Profilo, M. A., Mautone, T., Casini, G., Rocchi, R., & Marino, M. 2018. High serum cholesterol is a novel risk factor for graves' orbitopathy: results of a cross-sectional study. *Thyroid*, 28(3), 386-394.

- Salvi, M., 2018. "Step-down steroid-sparing therapy in active thyroid eye disease". *Nat Rev Endocrinol*, 14(11), hal.634-635.
- Saonanon, P., 2014. "Update on Asian eyelid anatomy and clinical relevance". *Curr Opin Ophthalmol*, 25(5), hal.436-442.
- Scott IU, Siatkowski MR., 1999. "Thyroid eye disease". *Semin Ophthalmol* 1999; 14:52–61. 2.
- Smith, T. J., 2010. "Pathogenesis of Graves' orbitopathy: A 2010 update". *J Endocrinol Invest*, 33(6), 414–421. doi:10.1007/bf03346614.
- Stein JD, Childers D, Gupta S., 2015. "Risk factors for developing thyroid-associated ophthalmopathy among individuals with Graves disease". *JAMA Ophthalmol* 2015; 133:290–296. 13.
- Subekti I, Boedisantoso A, Moeloek ND, Waspadji S, Mansyur M., 2012. "Association of TSH receptor antibody, thyroid stimulating antibody, and thyroid blocking antibody with clinical activity score and degree of severity of Graves ophthalmopathy". *Acta Med Indones*. 2012 Apr;44(2):114-21. PMID: 22745141.
- Subekti I., 2018. "Oftalmopati Graves: Perbandingan Karakteristik Klinis, Kadar Hormon, dan Kadar Antibodi Reseptor TSH". *eJKI* Vol. 6, No. 1 April 2018. doi: 10.23886/ejki.6.9299.
- Subekti, Imam. 2019. "Practical Guidelines Management of Graves Ophthalmopathy". *Acta Med Indonesia - Indonesia J Intern Med* • Vol 51 • Number 4 • October 2019.
- Takakura A, Kirkeby K, Earle K, Silkiss RZ., 2015. "Predicting the development of orbitopathy in Graves thyroidopathy patients: the potential role of TSI testing". *Ophthalmic Plast Reconstr Surg* 31(5):369–372.
- Tanda ML, Piantanida E, Liparulo L, Veronesi G, Lai A, Sassi L, Pariani N, Gallo D, Azzolini C, Ferrario M, Bartalena L., 2013. "Prevalence and natural history of Graves' orbitopathy in a large series of patients with newly diagnosed Graves' hyperthyroidism seen at a single center". *J Clin Endocrinol Metab* 98:1443–1449.
- Topilow, N.J., Tran, A.Q., Koo, E.B. and Alabiad, C.R., 2020. "Etiologies of Proptosis: A review". *Internal Med Rev (Washington, DC: Online)*, 6(3).
- Tu, X., Dong, Y., Zhang, H. and Su, Q., 2018. "Corticosteroids for Graves' ophthalmopathy: systematic review and meta-analysis". *BioMed research international*, 2018.
- Saonanon, P., 2014. "Update on Asian eyelid anatomy and clinical relevance". *Curr Op Ophthalmol*, 25(5), hal.436-442.
- Vanderpump M.P., Tunbridge W.M., French J.M., Appleton D., Bates D., Clark F., 1995. "The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham Survey". *Clin Endocrinol (Oxf)*, 43(1):55-68.
- Walpole, S.C., Prieto-Merino, D., Edwards, P., Cleland, J., Stevens, G. and Roberts, I., 2012. "The weight of nations: an estimation of adult human biomass". *BMC public health*, 12(1), hal.1-6.
- Wall JR, Lahooti H., 2010. "Pathogenesis of thyroid eye disease—does autoimmunity against the TSH receptor explain all cases". *Endokrynol Pol* 2010; 61:222–227. 3.

- Wang Y, Smith TJ., 2014. "Current concepts in the molecular pathogenesis of thyroid-associated ophthalmopathy". *Invest Ophthalmol Vis Sci.* 2014; 55:1735–48.
- Weetman AP., 2001. "Determinants of autoimmune thyroid disease". *Nat Immunol.* 2001;2:769–70.
- Wiersinga WM, Bartalena L., 2002. "Epidemiology and prevention of Graves' ophthalmopathy". *Thyroid* 2002; 12:855–860
- Zang, S., Ponto, K.A. and Kahaly, G.J., (2011). "Intravenous glucocorticoids for Graves' orbitopathy: efficacy and morbidity". *J Clin Endocr Met*, 96(2), hal.320-332.